Cytokinetics, Incorporated Cytokinetics, Incorporated

Cytokinetics, Incorporated

CYTK

株式のランク #2254
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on... Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
株価
$64.05
時価総額
$8.90B
変化（1日）
2.23%
変化（1年）
7.91%
国
US
取引 Cytokinetics, Incorporated (CYTK)

カテゴリー

Healthcare
Cytokinetics, Incorporated（CYTK）の株式分割履歴
Cytokinetics, Incorporated株（シンボル：CYTK）は合計で1回の株式分割を実施しました。
最新の株式分割はJun 25, 2013に行われました。
Jun 25, 2013より前に購入されたCYTK株は、現在0.16666666666667CYTK株に相当します。
株式分割一覧
年 株式分割 分割比率 累積分割比率
2013-06-25 1:6 x0.16666666666667 x0.16666666666667
類似企業または競合他社の株式分割
企業 株式分割の回数 累積分割比率 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 1 x2
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 0 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 1 x3
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 0 -
CH
Argenx SE Argenx SE
Argenx SE
ARGX.US
 0 -
NL